Database In Works To Help Drugmakers Avoid Molecules That Trigger Immune Reactions
Executive Summary
Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.
You may also be interested in...
How BMS Is Tackling Clinical Trial Diversity
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
FDA Email Alert: Next Day’s Manufacturing Volume Reporting Due Date Still Voluntary
Objections to 15 February reporting date established in draft guidance spurred rare last-minute notice assuring industry that it was a non-binding recommendation, not a requirement. Action reflects confusion that can arise in interpreting policy guidance.
Pharma Supply Chain Disruptions Increased Another 74% in 2021, Resilinc Says
The COVID-19 pandemic has both caused problems such as reduced preventive maintenance and exacerbated other issues, such as slowing recovery from extreme weather events, according to Resilinc CEO.